Moderna phase 1 results show coronavirus vaccine safe, induces immune response

Andrew Cummings
July 15, 2020

The candidate is reportedly generating the kind of immune response researchers were hoping to see, although efficacy has to be properly evaluated in the final phase of trials now undertaken in Brazil.

An experimental SARS-CoV2 (coronavirus) vaccine developed by the USA biotech firm Moderna was deemed to be safe and provoke an immune response in the first phase of a study whose findings published to The New England Journal of Medicine.

"The Adaptive Phase I/ II human clinical trials of its plasmid DNA vaccine, ZyCoV-D commenced today with the first human dosing".

After two vaccinations, the vaccine elicited a "robust" immune response in all participants in all dose cohorts, Moderna said.

So far, the coronavirus has infected more than 13.2 million people and killed 570,000 people worldwide.


He was referring to two Indian vaccine candidates that have undergone successful toxicity studies in rats, mice and rabbits.

In a press release, the company said analysis of trial results for its potential COVID-19 vaccine "mRNA-1273" reaffirmed the "positive interim data assessment" it announced mid-May when the drug first showed a "potential to prevent" the deadly and infectious coronavirus.

The group was the first United States company to test its vaccine on humans, however, it is not the only group with candidates in the works.

"It's a good first step", said Dr William Schaffner, a vaccine expert at Vanderbilt University Medical Center who was not involved in the study.

More than 100 possible vaccines are being developed and tested around the world to try to stop the pandemic. "Adverse events (AEs) were generally transient and mild to moderate in severity", Moderna said in a statement.


Moderna started its phase 2 trial in May and expects to begin a phase 3 trial at the end of this month.

Interestingly, President Donald Trump tweeted ' Great News On Vaccines', presumably referring to Moderna but possibly even to news of British Pharmaceutical Company AstraZeneca's Vaccine candidate.

An experimental COVID-19 vaccine that is being developed by U.S. biotech firm Moderna induced antibody responses against the coronavirus in all 45 participants of a human trial, a paper published Tuesday showed. This is a vaccine which is already in Phase 3 trial stage.

The company's vaccine arrived five and a half years after the virus emerged in West Africa, and this could explain why Kenneth Frazier, Merck's CEO, was cautious in a recent interview about the speed of vaccine development being seen against COVID-19.


Other reports by iNewsToday

FOLLOW OUR NEWSPAPER